1.	Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Phase: Phase IV Type: Treatment Status: Active Age: 16 to 75 Sponsor: Other Protocol IDs: CGC05MK1002, NCT00188149
2.	Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Phase: Phase III Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
3.	Phase III Randomized Study of Short- Versus Long-Infusion Schedule of Bleomycin in Patients Who are Undergoing Combination Chemotherapy Comprising Bleomycin, Etoposide, and Cisplatin for Good-Prognosis, Metastatic Germ Cell Cancer of the Testes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 to 50 Sponsor: Other Protocol IDs: BARTS-TE3, EU-20608, ISRCTN08648791, NCT00324298
4.	Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 15 to 70 Sponsor: Other Protocol IDs: CDR0000531125, EORTC-20051, GELA-H10, IIL-EORTC-20051, EUDRACT-2005-002765-37, EU-20657, NCT00433433
5.	Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
6.	HD18 for Advanced Stages in Hodgkins Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD18, NCT00515554
7.	Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-2007-006064-30, 2007-006064-30, CRUK-07/146, NCT00678327
8.	HD16 for Early Stage Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: HD16, NCT00736320
9.	High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: IIL-HD0801, EudracT Number 2008-002684-14, NCT00784537
10.	Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 16 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: ASI-HDIII 0109, NCT00816959
11.	Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
12.	R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FM-HD09-01, EudraCT N 2009-009431-30, NCT00992030
13.	HD17 for Intermediate Stage Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: HD17, NCT01356680
14.	Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 16 to 60 Sponsor: Other Protocol IDs: Casasnovas PHRC N 2010, NCT01358747
15.	Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018
16.	Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) Phase: Phase III Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 to 60 Sponsor: Other Protocol IDs: EORTC-20101-23101, 2011-005473-22, NCT01652261
17.	GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma Phase: Phase III Type: Diagnostic, Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: GAINED, NCT01659099
18.	Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C25003, 2011-005450-60, NCT01712490
19.	Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours Phase: Phase III Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ICR-CTSU/2008/10019, ISRCTN37875250, 2008-006295-29, 09/H1102/86, CRUK/09/011, NCT01726374
20.	A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CSWOG0002, NCT01788137
21.	Treatment of Liver Metastases With Electrochemotherapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 03-Z 16/KSOPKR-6, NCT01264952
22.	Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
23.	Phase II Randomized Study of Intensive Induction Chemotherapy Comprising Cisplatin, Vincristine, Bleomycin, and Carboplatin Followed By Bleomycin, Etoposide Phosphate, and Cisplatin (BEP) Versus Standard BEP Chemotherapy in Male Patients With Poor-Prognosis Extracranial Nonseminoma Germ Cell Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: MRC-TE23, EU-205107, ISRCTN53643604, EUDRACT-2004-000405-22, NCT00301782
24.	Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: ISRA2432_CTIL, NCT00392314
25.	Phase II Pilot Study of Bleomycin, Etoposide, Cisplatin, and Pegfilgrastim in Men With Metastatic Germ Cell Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 to 40 Sponsor: Other Protocol IDs: CRCA-CCTC-ACCELERATED-BEP, CCTC-ACCELERATED-BEP, EUDRACT-2004-000847-79, EU-20713, NCT00453232